{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,12,28]],"date-time":"2023-12-28T15:55:17Z","timestamp":1703778917974},"reference-count":57,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2005,9,1]],"date-time":"2005-09-01T00:00:00Z","timestamp":1125532800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Lymphoma and Myeloma"],"published-print":{"date-parts":[[2005,9]]},"DOI":"10.3816\/clm.2005.n.034","type":"journal-article","created":{"date-parts":[[2008,9,11]],"date-time":"2008-09-11T01:10:28Z","timestamp":1221095428000},"page":"89-95","source":"Crossref","is-referenced-by-count":8,"title":["Evolving Role of Stem Cell Transplantation in Multiple Myeloma"],"prefix":"10.3816","volume":"6","author":[{"given":"Jean-Luc","family":"Harousseau","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Moreau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.3816\/CLM.2005.n.034_bib1","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1056\/NEJM199607113350204","article-title":"A randomized prospective trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma","volume":"335","author":"Attal","year":"1996","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2005.n.034_bib2","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1056\/NEJMoa022340","article-title":"High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma","volume":"348","author":"Child","year":"2003","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2005.n.034_bib3","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1182\/blood-2004-02-0408","article-title":"Intermediate-dose melphalan improves survival of myeloma patients aged 50-70: results of a randomized controlled trial","volume":"104","author":"Palumbo","year":"2004","journal-title":"Blood"},{"key":"10.3816\/CLM.2005.n.034_bib4","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1182\/blood.V99.3.731","article-title":"Comparison of 200 mg\/m_melphalan and 8 Gy total body irradiation plus 140 mg\/m2 as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma. Final analysis of the IFM 95-02 randomized trial","volume":"99","author":"Moreau","year":"2002","journal-title":"Blood"},{"key":"10.3816\/CLM.2005.n.034_bib5","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1046\/j.1365-2141.2001.02976.x","article-title":"Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years","volume":"114","author":"Badros","year":"2001","journal-title":"Br J Haematol"},{"key":"10.3816\/CLM.2005.n.034_bib6","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1046\/j.1365-2141.2001.03033.x","article-title":"Results of autologous stem cell transplant in multiple myeloma patients with renal failure","volume":"114","author":"Badros","year":"2001","journal-title":"Br J Haematol"},{"key":"10.3816\/CLM.2005.n.034_bib7","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/sj.thj.6200003","article-title":"Are myeloma patients with renal failure candidate for autologous stem cell transplantation","volume":"1","author":"San Miguel","year":"2000","journal-title":"Hematol J"},{"key":"10.3816\/CLM.2005.n.034_bib8","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1182\/blood.V92.9.3131","article-title":"High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial","volume":"92","author":"Fermand","year":"1998","journal-title":"Blood"},{"issue":"suppl","key":"10.3816\/CLM.2005.n.034_bib9","first-page":"42a","article-title":"High-dose therapy\/autotransplantation\/intensification versus continued conventional chemotherapy in multiple myeloma patients responding to initial chemotherapy. Definitive results from PETHEMA after a median follow-up of 66 months","volume":"102","author":"Blade","year":"2003","journal-title":"Blood"},{"issue":"suppl","key":"10.3816\/CLM.2005.n.034_bib10","doi-asserted-by":"crossref","first-page":"539a","DOI":"10.1182\/blood.V104.11.539.539","volume":"104","author":"Crowley","year":"2004","journal-title":"Blood"},{"key":"10.3816\/CLM.2005.n.034_bib11","first-page":"148a","article-title":"A prospective randomized trial of oral melphalan, prednisone, thalidomide (MPT) vs oral melphalan, prednisone (MP): an interim analysis","volume":"102","author":"Palumbo","year":"2003","journal-title":"Blood"},{"issue":"suppl 1","key":"10.3816\/CLM.2005.n.034_bib12","first-page":"56","article-title":"Melphalan prednisone (MP), MPthalidomide and high-dose therapy using melphalan 100 mg\/m2 for newly diagnosed myeloma patients ages 65-75 years: interim analysis of the IFM99-06 trial on 350 patients","volume":"90","author":"Facon","year":"2005","journal-title":"Haematologica"},{"key":"10.3816\/CLM.2005.n.034_bib13","first-page":"221","article-title":"Multiple myeloma","author":"Anderson","year":"2002","journal-title":"American Society of Hematology Program Educational Book"},{"key":"10.3816\/CLM.2005.n.034_bib14","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1182\/blood.V79.11.2827.bloodjournal79112827","article-title":"Double intensive therapy in high-risk multiple myeloma","volume":"79","author":"Harousseau","year":"1992","journal-title":"Blood"},{"key":"10.3816\/CLM.2005.n.034_bib15","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1182\/blood.V88.3.838.838","article-title":"Autotransplant in multiple myeloma: what have we learned?","volume":"88","author":"Vesole","year":"1996","journal-title":"Blood"},{"key":"10.3816\/CLM.2005.n.034_bib16","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1182\/blood.V93.1.55","article-title":"Total therapy with tandem transplant for newly diagnosed multiple myeloma","volume":"93","author":"Barlogie","year":"1999","journal-title":"Blood"},{"key":"10.3816\/CLM.2005.n.034_bib17","doi-asserted-by":"crossref","first-page":"4008","DOI":"10.1182\/blood.V95.12.4008","article-title":"Results of high dose therapy for 1000 patients with multiple myeloma: durable complete remission and superior survival in the absence of chromosome 13 abnormalities","volume":"95","author":"Desikan","year":"2000","journal-title":"Blood"},{"key":"10.3816\/CLM.2005.n.034_bib18","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa032290","article-title":"Single versus double autologous stem cell transplantation for multiple myeloma","volume":"349","author":"Attal","year":"2003","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"10.3816\/CLM.2005.n.034_bib19","first-page":"37","article-title":"Intensive versus double intensive therapy in untreated multiple myeloma. Updated analysis of the prospective phase III study Hovon 24-MM","volume":"90","author":"Sonneveld","year":"2005","journal-title":"Haematologica"},{"issue":"suppl 1","key":"10.3816\/CLM.2005.n.034_bib20","first-page":"39","article-title":"Single versus tandem autologous transplants in multiple myeloma: Italian experience","volume":"90","author":"Cavo","year":"2005","journal-title":"Haematologica"},{"issue":"suppl 1","key":"10.3816\/CLM.2005.n.034_bib21","first-page":"38","article-title":"Single versus double high dose therapy in multiple myeloma: second analysis of the trial GMMG-HD2","volume":"90","author":"Goldschmidt","year":"2005","journal-title":"Haematologica"},{"key":"10.3816\/CLM.2005.n.034_bib22","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1046\/j.1365-2141.2002.03757.x","article-title":"Both hypodiploidy and deletion of chromosome 13 independently confer post prognosis in multiple myeloma","volume":"118","author":"Fassas","year":"2002","journal-title":"Br J Haematol"},{"key":"10.3816\/CLM.2005.n.034_bib23","doi-asserted-by":"crossref","first-page":"3849","DOI":"10.1182\/blood-2002-09-2873","article-title":"Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy ensure long-term survival in myeloma treated with Total Therapy I: interpretation in the context of global gene expression","volume":"101","author":"Shaughnessy","year":"2003","journal-title":"Blood"},{"key":"10.3816\/CLM.2005.n.034_bib24","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1182\/blood.V97.6.1566","article-title":"Chromosome 13 abnormalities identified by FISH analysis and serum ?2 microglobulin produce powerful myeloma staging system for patients receiving high-dose therapy","volume":"97","author":"Facon","year":"2001","journal-title":"Blood"},{"issue":"suppl 1","key":"10.3816\/CLM.2005.n.034_bib25","first-page":"55","article-title":"Final results of the IFM 9904 protocol: double transplant + anti-interleukin-6 monoclonal antibody in highrisk de novo multiple myeloma patients less than 65 years old","volume":"90","author":"Moreau","year":"2005","journal-title":"Haematologica"},{"issue":"suppl","key":"10.3816\/CLM.2005.n.034_bib26","first-page":"560s","article-title":"Results of total therapy 2 (TT 2), a phase III randomized trial, to determine the role of thalidomide (Thal) in the upfront management of multiple myeloma (MM)","volume":"23","author":"Barlogie","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2005.n.034_bib27","doi-asserted-by":"crossref","first-page":"4319","DOI":"10.1200\/JCO.2002.02.116","article-title":"Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma","volume":"20","author":"Rajkumar","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2005.n.034_bib28","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1200\/JCO.2003.03.139","article-title":"Thalidomide alone or with dexamethasone for previously untreated multiple myeloma","volume":"21","author":"Weber","year":"2003","journal-title":"J Clin Oncol"},{"issue":"suppl","key":"10.3816\/CLM.2005.n.034_bib29","first-page":"98a","article-title":"Combination therapy with CC- 5013 (lenalidomide; Revlimid\u2122) plus dexamethasone (Rev\/Dex) for newly diagnosed myeloma (MM)","volume":"104","author":"Rajkumar","year":"2004","journal-title":"Blood"},{"key":"10.3816\/CLM.2005.n.034_bib30","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1182\/blood-2005-02-0522","article-title":"Superiority of thalidomide and dexamethasone over vincristine-doxorubicin-dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma","volume":"106","author":"Cavo","year":"2005","journal-title":"Blood"},{"key":"10.3816\/CLM.2005.n.034_bib31","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","article-title":"A phase 2 study of bortezomib in relapsed, refractory myeloma","volume":"348","author":"Richardson","year":"2003","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2005.n.034_bib32","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1365-2141.2004.05188.x","article-title":"A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma","volume":"127","author":"Jagannath","year":"2004","journal-title":"Br J Haematol"},{"key":"10.3816\/CLM.2005.n.034_bib33","doi-asserted-by":"crossref","first-page":"100a","DOI":"10.1182\/blood.V104.11.336.336","article-title":"Phase II trial of single agent bortezomib in patients with previously untreated multiple myeloma","volume":"104","author":"Richardson","year":"2004","journal-title":"Blood"},{"key":"10.3816\/CLM.2005.n.034_bib34","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1111\/j.1365-2141.2005.05540.x","article-title":"Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma","volume":"129","author":"Jagannath","year":"2005","journal-title":"Br J Haematol"},{"key":"10.3816\/CLM.2005.n.034_bib35","doi-asserted-by":"crossref","first-page":"598s","DOI":"10.1200\/jco.2005.23.16_suppl.6653","article-title":"Bortezomib (VELCADE\u00ae) plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: preliminary results of an IFM phase II study","volume":"23","author":"Harousseau","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2005.n.034_bib36","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1111\/j.1365-2141.2005.05519.x","article-title":"PAD combination therapy (PS- 341\/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma","volume":"129","author":"Oakervee","year":"2005","journal-title":"Br J Haematol"},{"key":"10.3816\/CLM.2005.n.034_bib37","doi-asserted-by":"crossref","first-page":"156a","DOI":"10.1182\/blood.V104.11.538.538","article-title":"Total therapy 3 for newly diagnosed myeloma, incorporating Velcade into remission induction with DTPACE; early results regarding efficacy, PBSC mobilization and toxicities","volume":"104","author":"Barlogie","year":"2004","journal-title":"Blood"},{"key":"10.3816\/CLM.2005.n.034_bib38","first-page":"64a","article-title":"VTD (Velcade, thalidomide, dexamethasone) as primary treatment for newly diagnosed multiple myeloma","volume":"104","author":"Alexanian","year":"2004","journal-title":"Blood"},{"key":"10.3816\/CLM.2005.n.034_bib39","doi-asserted-by":"crossref","first-page":"266a","DOI":"10.1182\/blood.V104.11.929.929","article-title":"Addition of bortezomib to high-dose melphalan as an effective conditioning regimen with autologous stem cell support in multiple myeloma","volume":"104","author":"Hollmig","year":"2004","journal-title":"Blood"},{"key":"10.3816\/CLM.2005.n.034_bib40","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/sj.bmt.1702826","article-title":"Alpha-interferon maintenance treatment is associated with improved survival after high-dose treatment and autologous stem cell transplantation in patients with multiple myeloma: a retrospective registry study from the EBMT","volume":"27","author":"Bjorkstrand","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"10.3816\/CLM.2005.n.034_bib41","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1046\/j.1365-2141.1998.00795.x","article-title":"A randomized trial of maintenance interferon following high-dose therapy in multiple myeloma: longterm follow-up results","volume":"102","author":"Cunningham","year":"1998","journal-title":"Br J Haematol"},{"issue":"suppl 1","key":"10.3816\/CLM.2005.n.034_bib42","first-page":"17","article-title":"Maintenance treatment with thalidomide and pamidronate after autologous transplantation for myeloma: second analysis of a prospective randomized study of the Intergroupe Francophone du Myelome","volume":"90","author":"Attal","year":"2005","journal-title":"Haematologica"},{"key":"10.3816\/CLM.2005.n.034_bib43","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1182\/blood-2002-03-0996","article-title":"A phase I trial of oral CC- 5013 an immunomodulatory thalidomide derivative in patients with relapsed and refractory multiple myeloma","volume":"100","author":"Richardson","year":"2002","journal-title":"Blood"},{"issue":"suppl","key":"10.3816\/CLM.2005.n.034_bib44","first-page":"104a","article-title":"A multi-center randomized, phase II study to evaluate the efficacy and safety of two CC-5013 dose regimens, when used alone or in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma","volume":"100","author":"Richardson","year":"2002","journal-title":"Blood"},{"key":"10.3816\/CLM.2005.n.034_bib45","doi-asserted-by":"crossref","first-page":"4362","DOI":"10.1182\/blood-2003-11-3862","article-title":"The occurrence of graft-versus host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma","volume":"103","author":"Lockhorst","year":"2004","journal-title":"Blood"},{"key":"10.3816\/CLM.2005.n.034_bib46","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1200\/JCO.2003.04.033","article-title":"Partially T-cell depleted allogeneic stem-cell transplantation for first-line treatment of multiple myeloma: a prospective evaluation of patients treated in the phase III Hovon 24 MM","volume":"21","author":"Lockhorst","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2005.n.034_bib47","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1046\/j.1365-2141.2001.02726.x","article-title":"Progress in allogeneic bone marrow and peripheral stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983-93 and 1994-98 at European Group for Blood and Marrow Transplantation","volume":"113","author":"Gahrton","year":"2001","journal-title":"Br J Haematol"},{"key":"10.3816\/CLM.2005.n.034_bib48","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1182\/blood-2003-04-1045","article-title":"Treatment of multiple myeloma","volume":"103","author":"Barlogie","year":"2004","journal-title":"Blood"},{"key":"10.3816\/CLM.2005.n.034_bib49","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/sj.bmt.1703652","article-title":"Fludarabine\/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma","volume":"30","author":"Giralt","year":"2002","journal-title":"Bone Marrow Transplant"},{"key":"10.3816\/CLM.2005.n.034_bib50","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1046\/j.1365-2141.2003.04299.x","article-title":"Follow-up of patients with multiple myeloma undergoing allografts after reduced-intensity conditioning","volume":"121","author":"Einsele","year":"2003","journal-title":"Br J Haematol"},{"key":"10.3816\/CLM.2005.n.034_bib51","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1200\/JCO.20.5.1295","article-title":"Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after non myeloablative conditioning","volume":"20","author":"Badros","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2005.n.034_bib52","doi-asserted-by":"crossref","first-page":"3919","DOI":"10.1182\/blood-2002-04-1150","article-title":"Unrelated stem cell transplantation in multiple myeloma after reduced intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality","volume":"100","author":"Kroger","year":"2002","journal-title":"Blood"},{"key":"10.3816\/CLM.2005.n.034_bib53","first-page":"244","year":"2004","journal-title":"American Society of Hematology Program Educational Book"},{"key":"10.3816\/CLM.2005.n.034_bib54","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1182\/blood-2002-09-2955","article-title":"Allografting with non myeloablative conditioning following cytoreductive autograft for the treatment of patients with multiple myeloma","volume":"102","author":"Maloney","year":"2003","journal-title":"Blood"},{"key":"10.3816\/CLM.2005.n.034_bib55","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1182\/blood-2002-01-0131","article-title":"Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma","volume":"100","author":"Kroger","year":"2002","journal-title":"Blood"},{"key":"10.3816\/CLM.2005.n.034_bib56","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/sj.bmt.1704531","article-title":"Graft-versus-myeloma effect following antiothymocyte globulin-based reduced intensity conditioning allogeneic stem cell transplantation","volume":"43","author":"Mohty","year":"2004","journal-title":"Bone Marrow Transplant"},{"issue":"suppl","key":"10.3816\/CLM.2005.n.034_bib57","first-page":"43a","article-title":"Preliminary results of IFM 9903 and 9904 protocols comparing autologous followed by miniallotransplantation and double autologous transplantation in high-risk de novo multiple myeloma","volume":"102","author":"Moreau","year":"2003","journal-title":"Blood"}],"container-title":["Clinical Lymphoma and Myeloma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1557919011703754?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1557919011703754?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T06:09:43Z","timestamp":1588918183000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1557919011703754"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,9]]},"references-count":57,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2005,9]]}},"alternative-id":["S1557919011703754"],"URL":"https:\/\/doi.org\/10.3816\/clm.2005.n.034","relation":{},"ISSN":["1557-9190"],"issn-type":[{"value":"1557-9190","type":"print"}],"subject":[],"published":{"date-parts":[[2005,9]]}}}